Jong-Hyeok Kim

Author PubWeight™ 66.83‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. Gynecol Oncol 2011 2.76
2 Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes. Gynecol Oncol 2008 1.89
3 Laparoscopic management of early uterine cancer: 10-year experience in Asan Medical Center. Gynecol Oncol 2007 1.81
4 Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin. Gynecol Oncol 2012 1.49
5 Malignant transformation of mature cystic teratoma of the ovary: experience at a single institution. Eur J Obstet Gynecol Reprod Biol 2008 1.09
6 Surgical management of borderline ovarian tumors: The role of fertility-sparing surgery. Gynecol Oncol 2009 1.06
7 Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer. J Gynecol Oncol 2008 1.06
8 Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007. J Cancer Res Clin Oncol 2008 1.05
9 Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer. Gynecol Oncol 2008 1.04
10 The impact of tumor morcellation during surgery on the outcomes of patients with apparently early low-grade endometrial stromal sarcoma of the uterus. Ann Surg Oncol 2011 1.03
11 Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability. Biochemistry 2004 1.02
12 Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. J Gynecol Oncol 2008 0.99
13 Is complete surgical staging necessary in patients with stage I mucinous epithelial ovarian tumors? Gynecol Oncol 2006 0.98
14 Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. Mol Cancer Ther 2002 0.97
15 Further stratification of risk groups in patients with lymph node metastasis after radical hysterectomy for early-stage cervical cancer. Gynecol Oncol 2010 0.97
16 Neoadjuvant chemotherapy with paclitaxel plus platinum followed by radical surgery in early cervical cancer during pregnancy: three case reports. Jpn J Clin Oncol 2010 0.95
17 Laparoscopic versus open radical hysterectomy in patients with stage IB2 and IIA2 cervical cancer. J Surg Oncol 2013 0.94
18 Comparison of laparoscopy and laparotomy in surgical staging of early-stage ovarian and fallopian tubal cancer. Ann Surg Oncol 2008 0.94
19 Peroxiredoxin 6 overexpression attenuates cisplatin-induced apoptosis in human ovarian cancer cells. Cancer Invest 2011 0.94
20 Vaginal cuff dehiscence after hysterectomy. Int J Gynaecol Obstet 2013 0.94
21 Differential gene expression profiling in human cholangiocarcinoma cells treated with Clonorchis sinensis excretory-secretory products. Parasitol Res 2008 0.93
22 Surgical staging and adjuvant chemotherapy in the management of patients with adult granulosa cell tumors of the ovary. Gynecol Oncol 2011 0.93
23 Comparison of outcomes between radical hysterectomy followed by tailored adjuvant therapy versus primary chemoradiation therapy in IB2 and IIA2 cervical cancer. J Gynecol Oncol 2012 0.93
24 High-dose extended-field irradiation and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys 2009 0.92
25 Unfavorable prognosis of small cell neuroendocrine carcinoma of the uterine cervix: a retrospective matched case-control study. Int J Gynecol Cancer 2010 0.91
26 Laparoscopic versus open radical hysterectomy for elderly patients with early-stage cervical cancer. Am J Obstet Gynecol 2012 0.90
27 Surgical practice patterns in endometrial cancer: results of the Korean Gynecologic Oncology Group survey. J Gynecol Oncol 2009 0.89
28 The efficacy of conservative management after conization in patients with stage IA1 microinvasive cervical carcinoma. Acta Obstet Gynecol Scand 2009 0.89
29 Long-term outcomes after fertility-sparing laparoscopic radical trachelectomy in young women with early-stage cervical cancer: an Asan Gynecologic Cancer Group (AGCG) study. J Surg Oncol 2014 0.88
30 The effect of combined treatment with cisplatin and histone deacetylase inhibitors on HeLa cells. J Gynecol Oncol 2010 0.87
31 Pure primary squamous cell carcinoma of the ovary: a report of two cases and review of the literature. Int J Gynecol Pathol 2010 0.86
32 Role of PET or PET/CT in the post-therapy surveillance of uterine sarcoma. Gynecol Oncol 2008 0.86
33 Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Eur J Cancer 2012 0.86
34 The role of pelvic and/or para-aortic lymphadenectomy in surgical management of apparently early carcinosarcoma of uterus. Ann Surg Oncol 2010 0.85
35 Radiation therapy is a treatment to be considered for recurrent epithelial ovarian cancer after chemotherapy. Tumori 2011 0.85
36 The relationship between cisplatin resistance and histone deacetylase isoform overexpression in epithelial ovarian cancer cell lines. J Gynecol Oncol 2012 0.85
37 Progression-free survival is accurately predicted in patients treated with chemotherapy for epithelial ovarian cancer by the histoculture drug response assay in a prospective correlative clinical trial at a single institution. Anticancer Res 2013 0.85
38 Proliferation of CD4CD25Foxp3 regulatory T lymphocytes in ex vivo expanded ascitic fluid from primary and recurrent ovarian carcinoma. J Gynecol Oncol 2010 0.85
39 Prognostic factors in women with synchronous endometrial and ovarian cancers. Int J Gynecol Cancer 2014 0.85
40 Is chemotherapy-induced neutropenia a prognostic factor in patients with ovarian cancer? Acta Obstet Gynecol Scand 2010 0.84
41 Micropapillary pattern in serous borderline ovarian tumors: does it matter? Gynecol Oncol 2011 0.84
42 Laparoscopic compared with open radical hysterectomy in obese women with early-stage cervical cancer. Obstet Gynecol 2012 0.83
43 Identification of differentially expressed microRNAs in endometrial cancer cells after progesterone treatment. Int J Gynecol Cancer 2012 0.83
44 Secondary cytoreductive surgery in the management of platinum-sensitive recurrent epithelial ovarian cancer. J Surg Oncol 2010 0.83
45 Human papillomavirus test after conization in predicting residual disease in subsequent hysterectomy specimens. Obstet Gynecol 2009 0.83
46 In vitro chemosensitivity using the histoculture drug response assay in human epithelial ovarian cancer. Acta Med Okayama 2012 0.82
47 Association between low SIRT1 expression in visceral and subcutaneous adipose tissues and metabolic abnormalities in women with obesity and type 2 diabetes. Diabetes Res Clin Pract 2013 0.82
48 Risk assessment model for overall survival in patients with locally advanced cervical cancer treated with definitive concurrent chemoradiotherapy. Gynecol Oncol 2012 0.82
49 Comparative study of neoadjuvant chemotherapy before radical hysterectomy and radical surgery alone in stage IB2-IIA bulky cervical cancer. J Gynecol Oncol 2009 0.82
50 Hormonal therapy for women with stage IA endometrial cancer of all grades. Obstet Gynecol 2013 0.81
51 Laparoendoscopic single-site versus conventional laparoscopic surgical staging for early-stage endometrial cancer. Int J Gynecol Cancer 2014 0.81
52 Relationship between vaspin gene expression and abdominal fat distribution of Korean women. Endocr J 2011 0.81
53 Concurrent chemoradiotherapy or radiotherapy alone for locally advanced cervical cancer in elderly women. Tumori 2011 0.81
54 Ex vivo expansion of human umbilical cord blood-derived T-lymphocytes with homologous cord blood plasma. Tohoku J Exp Med 2005 0.80
55 Laparoscopic management of early-stage malignant nonepithelial ovarian tumors: surgical and survival outcomes. Int J Gynecol Cancer 2013 0.79
56 IL-34 is associated with obesity, chronic inflammation, and insulin resistance. J Clin Endocrinol Metab 2014 0.79
57 Prognostic significance of stromal microinvasion in the intestinal type of ovarian mucinous adenocarcinoma. Ann Surg Oncol 2011 0.79
58 Feasibility and outcome of concurrent chemoradiotherapy for recurrent cervical carcinoma after initial surgery. Tumori 2010 0.79
59 Preoperative fluorine 18 fluorodeoxyglucose tumoral uptake ratio between upper and lower abdomen in primary advanced-stage ovarian cancer. Int J Gynecol Cancer 2013 0.78
60 Mutational analysis of KRAS, BRAF, and TP53 genes of ovarian serous carcinomas in Korean women. Yonsei Med J 2009 0.78
61 Optimal debulking surgery followed by paclitaxel/platinum chemotherapy is very effective in treating ovarian carcinosarcomas: a single center experience. Gynecol Obstet Invest 2011 0.78
62 Poor prognosis of uterine serous carcinoma compared with grade 3 endometrioid carcinoma in early stage patients. Virchows Arch 2013 0.78
63 Incremental value of cell block preparations over conventional smears alone in the evaluation of EUS-FNA for pancreatic masses. Hepatogastroenterology 2014 0.78
64 Outcomes of Surgery Alone and Surveillance Strategy in Young Women With Stage I Malignant Ovarian Germ Cell Tumors. Int J Gynecol Cancer 2016 0.78
65 Chemosensitivity of uterine cervical cancer demonstrated by the histoculture drug response assay. Tohoku J Exp Med 2009 0.77
66 The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer. J Chemother 2010 0.77
67 Transcriptional regulation of the murine 1-cys peroxiredoxin gene by the B cell-specific activator protein, Pax5. J Cell Biochem 2008 0.77
68 Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer. Gynecol Oncol 2008 0.77
69 A comparative study of outside-in and inside-out transobturator tape procedures for stress urinary incontinence. Gynecol Obstet Invest 2010 0.76
70 Reliability of magnetic resonance imaging in assessing myometrial invasion absence in endometrial carcinoma. Acta Obstet Gynecol Scand 2009 0.76
71 Laparoendoscopic single-site versus conventional laparoscopic-assisted vaginal hysterectomy for benign or pre-invasive uterine disease. Surg Endosc 2014 0.76
72 Hexamethylmelamine as consolidation treatment for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy. J Korean Med Sci 2009 0.75
73 Postoperative acute renal failure in patients with gynecologic malignancies: analysis of 10 cases and review of the literature. J Gynecol Oncol 2009 0.75
74 Erratum: Author correction. Obstet Gynecol Sci 2017 0.75
75 Identification of a preoperative predictive factor for lymph node metastasis in uterine papillary serous carcinoma: long-term results from a single institution. Int J Gynecol Cancer 2015 0.75
76 Fibronectin gene expression in human adipose tissue and its associations with obesity-related genes and metabolic parameters. Obes Surg 2013 0.75
77 A Long-term follow-up study of 91 cases with ovarian granulosa cell tumors. Anticancer Res 2014 0.75
78 Significance of Ovarian Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma. Int J Gynecol Cancer 2017 0.75
79 Stratification of risk groups according to survival after recurrence in endometrial cancer patients. Medicine (Baltimore) 2017 0.75
80 Investigation of New Therapeutic Targets in Undifferentiated Endometrial Sarcoma. Gynecol Obstet Invest 2017 0.75
81 Paget's disease of the vulva: evaluation of recurrence relative to symptom duration, volumetric excision of lesion, and surgical margin status. Acta Obstet Gynecol Scand 2010 0.75
82 Preoperative Predictive Factors for Complete Cytoreduction and Survival Outcome in Epithelial Ovarian, Tubal, and Peritoneal Cancer After Neoadjuvant Chemotherapy. Int J Gynecol Cancer 2017 0.75